Urogen Pharma Ltd- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Urogen Pharma Ltd 公司

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Urogen Pharma Ltd简介



公司代码URGN

公司名称Urogen Pharma Ltd

上市日期May 04, 2017

CEOBarrett (Elizabeth A)

员工数量235

证券类型Ordinary Share

年结日May 04

公司地址9 Ha'ta'asiya St

城市RA'ANANA

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Israel

邮编4365007

电话97297707601

网址https://www.urogen.com/

公司代码URGN

上市日期May 04, 2017

CEOBarrett (Elizabeth A)

Urogen Pharma Ltd公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

--

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.69K

--

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

43.30K

+1813.00%

Mr. Christopher (Chris) Degnan

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

2.28K

+2280.00%

Ms. Cynthia M. Butitta

Independent Director

2.00K

+2000.00%

Dr. Stuart Holden, M.D.

Independent Director

--

Dr. Mark P. Schoenberg, M.D.

Chief Medical Officer

--

Mr. Vincent Perrone

Investor Relations

--

Dr. Leana S. Wen, M.D.

Independent Director

--

Mr. Daniel G. Wildman

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

--

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.69K

--

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

43.30K

+1813.00%

Mr. Christopher (Chris) Degnan

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

2.28K

+2280.00%

Ms. Cynthia M. Butitta

Independent Director

2.00K

+2000.00%

Dr. Stuart Holden, M.D.

Independent Director

--

收入明细

单位: USD更新时间: 1月6日周二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

业务USD

名称

营收

占比

Jelmyto

25.70M

93.53%

Zusduri

1.78M

6.47%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Jelmyto

25.70M

93.53%

Zusduri

1.78M

6.47%

股东统计

更新时间: 2月7日周六

持股股东

股东类型

持股股东

占比

RTW Investments L.P.

9.71%

Paradigm BioCapital Advisors LP

9.01%

TD Securities, Inc.

6.82%

Morgan Stanley & Co. LLC

5.25%

Jefferies LLC

4.70%

其他

64.52%

持股股东

占比

RTW Investments L.P.

9.71%

Paradigm BioCapital Advisors LP

9.01%

TD Securities, Inc.

6.82%

Morgan Stanley & Co. LLC

5.25%

Jefferies LLC

4.70%

其他

64.52%

股东类型

持股股东

占比

Hedge Fund

29.37%

Research Firm

22.98%

Investment Advisor

22.01%

Investment Advisor/Hedge Fund

19.50%

Insurance Company

4.14%

Individual Investor

2.09%

Corporation

1.79%

Private Equity

1.47%

Bank and Trust

0.25%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

321

48.31M

103.21%

-13.86M

2025Q3

311

45.66M

97.55%

-6.58M

2025Q2

285

53.00M

114.72%

+5.27M

2025Q1

290

49.25M

108.64%

+1.67M

2024Q4

280

43.94M

103.24%

-1.94M

2024Q3

262

44.13M

104.63%

-2.19M

2024Q2

247

46.02M

111.40%

+11.07M

2024Q1

255

34.96M

99.86%

+5.57M

2023Q4

237

29.16M

94.80%

+4.33M

2023Q3

238

25.93M

86.41%

+2.69M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

RTW Investments L.P.

4.54M

9.71%

--

Sep 30, 2025

Paradigm BioCapital Advisors LP

4.22M

9.01%

+1.88M

+80.79%

Sep 30, 2025

TD Securities, Inc.

3.19M

6.82%

--

Sep 30, 2025

Morgan Stanley & Co. LLC

2.46M

5.25%

+983.01K

+66.65%

Sep 30, 2025

Jefferies LLC

2.20M

4.7%

--

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

2.14M

4.58%

+33.75K

+1.60%

Sep 30, 2025

SilverArc Capital Management, LLC

1.58M

3.37%

-445.20K

-22.01%

Sep 30, 2025

Millennium Management LLC

1.47M

3.14%

+874.71K

+147.25%

Sep 30, 2025

UBS Asset Management Switzerland AG

1.32M

2.82%

--

Jan 31, 2025

Acorn Capital Advisors, LLC

1.26M

2.69%

--

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

ARK Israel Innovative Technology ETF

2.09%

Tema Oncology ETF

1.92%

ALPS Medical Breakthroughs ETF

0.39%

Hypatia Women CEO ETF

0.28%

ProShares Ultra Nasdaq Biotechnology

0.16%

iShares Micro-Cap ETF

0.15%

Fidelity Enhanced Small Cap ETF

0.11%

Vanguard US Momentum Factor ETF

0.1%

Invesco Nasdaq Biotechnology ETF

0.09%

iShares Biotechnology ETF

0.07%

ARK Israel Innovative Technology ETF

占比2.09%

Tema Oncology ETF

占比1.92%

ALPS Medical Breakthroughs ETF

占比0.39%

Hypatia Women CEO ETF

占比0.28%

ProShares Ultra Nasdaq Biotechnology

占比0.16%

iShares Micro-Cap ETF

占比0.15%

Fidelity Enhanced Small Cap ETF

占比0.11%

Vanguard US Momentum Factor ETF

占比0.1%

Invesco Nasdaq Biotechnology ETF

占比0.09%

iShares Biotechnology ETF

占比0.07%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据